logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10723711 B1

PDFFull Text
Date of Patent:
Jul. 28, 2020

Filed:

Aug. 21, 2019

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Christopher Ryan Butler, Canton, MA (US);

Laura Ann McAllister, Arlington, MA (US);

Elizabeth Mary Beck, Abingdon, GB;

Michael Aaron Brodney, Newton, MA (US);

Adam Matthew Gilbert, Guilford, CT (US);

Christopher John Helal, Mystic, CT (US);

Douglas Scott Johnson, Concord, MA (US);

Justin Ian Montgomery, Ledyard, CT (US);

Steven Victor O'Neil, East Lyme, CT (US);

Bruce Nelsen Rogers, Belmont, MA (US);

Patrick Robert Verhoest, Newton, MA (US);

Damien Webb, Brookline, MA (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:

Feng Shao

Primary Examiner:

Rita J Desai

Int. Cl.
CPC ...
C07D 295/14 (2006.01); C07D 401/14 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 498/10 (2006.01); C07D 491/107 (2006.01); C07D 401/12 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 211/48 (2006.01); C07D 471/08 (2006.01); C07D 515/10 (2006.01); C07F 9/6561 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 405/12 (2006.01); C07D 493/10 (2006.01);
U.S. Cl.
CPC ...
C07D 295/14 (2013.01); C07D 211/48 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/08 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01); C07D 493/10 (2013.01); C07D 498/10 (2013.01); C07D 515/10 (2013.01); C07F 9/6561 (2013.01);
Abstract

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Find Patent Forward Citations

Loading…